Skip to main content
Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

Table 1.

pIC50 values of the reported 2-Phenylindole derivatives against EGFR, CDK2 and Tubulin.

More »

Table 1 Expand

Fig 1.

(a) 3D-QSAR structure superposition of training set (b) compound 5n as a template.

More »

Fig 1 Expand

Fig 2.

CoMSIA contour maps: (A) Steric, (B) Electrostatic, (C) Hydrophobic, (D) Hydrogen bond donor, and (E) Hydrogen bond acceptor fields, displayed with a grid spacing of 2.0 Å and combined with compound 5n.

More »

Fig 2 Expand

Table 2.

The selected targets and the coordinates of the grid box.

More »

Table 2 Expand

Table 3.

Statistical results of CoMSIA models with different combinations of molecular fields.

More »

Table 3 Expand

Table 4.

Predicted pIC50 values and corresponding CoMSIA descriptors for the compounds in this study (*: test set).

More »

Table 4 Expand

Table 5.

Statistical parameters for validating the CoMSIA/SEHDA model.

More »

Table 5 Expand

Fig 3.

Structure-activity relationship derived from CoMSIA- SEHDA.

More »

Fig 3 Expand

Fig 4.

Structures and Predicted pIC50 Activities (Pred) According to the 3D-QSAR Model for Predicted Compounds.

More »

Fig 4 Expand

Table 6.

ADMET properties of selected molecules including the most active compound.

More »

Table 6 Expand

Table 7.

Docking score of the identified compounds against Cyclin-Dependent Kinase 2 (PDB ID: 2A4L), Tubulin (PDB ID: 1AS0), and Epidermal Growth Factor Receptor tyrosine kinase (PDB ID: 1M17) for anti-cancer activity.

More »

Table 7 Expand

Fig 5.

Docking simulation of the interaction between (A) Ligand Pred9, (B) Ligand Pred10 and

(C) Roscovitine (reference drug) with CDK2 protein.

More »

Fig 5 Expand

Fig 6.

Docking simulation of the interaction between (A) Ligand Pred9, (B) Ligand Pred10 and

(C) Colchicine (reference drug) with Tubulin protein.

More »

Fig 6 Expand

Fig 7.

Docking simulation of the interaction between (A) Ligand Pred9, (B) Ligand Pred10 and

(C) Erlotinib (reference drug) with EGFR protein.

More »

Fig 7 Expand

Fig 8.

RMSD Analysis of Active Molecules Pred9 and Pred10 in Complex with A: Tubulin, B: CDK2, and C: EGFR.

More »

Fig 8 Expand

Fig 9.

RMSF Analysis of Active Molecule, Pred9, and Pred10 in Complex with A: Tubulin, B: CDK2, and C: EGFR.

More »

Fig 9 Expand

Fig 10.

Radius of gyration Analysis of Active Molecule, Pred9, and Pred10 in Complex with A: Tubulin, B: CDK2, and C: EGFR.

More »

Fig 10 Expand

Fig 11.

H-bond Analysis of Active Molecule, Pred9, and Pred10 in Complex with A: Tubulin, B: CDK2, and C: EGFR.

More »

Fig 11 Expand